Glucagon-like peptide-1 receptor (GLP-1R) agonists may potentially exert neuroprotective effects against nervous system diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This evidence concerns the gene GLP1R and Alzheimer disease.